CD8A and neoplasm: In a phase I dose-escalation study involving intratumoral administration in patients with advanced solid tumors, the oncolytic peptide LTX-315 demonstrated ideal patient tolerance and therapeutic efficacy, including tumor regression in some patients and a significant reduction in tumor volume in 30% of cases, promoting CD8+ T-cell infiltration within tumors and inducing distant responses [59].